Bayer reports phase I results for prostate cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Bayer earnings preview: Recent focus on asundexian momentum ahead of Q4 results
March 3, 2026 6:00 PM ESTBayer AG (OTC: BAYRY) reports fourth-quarter and full-year 2025 results on Wednesday, with analysts more recently focusing on the companys litigation overhang and Asundexian stroke data.
Consensus forecasts point to sales of 11.34 billion for Q4 2025 and 45.48 billion for the full year. Net income is expected to remain negative for 2025, with analysts on average forecasting a 223 million... More
